BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 15742545)

  • 21. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
    Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
    J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial.
    Wefel JS; Lenzi R; Theriault RL; Davis RN; Meyers CA
    Cancer; 2004 Jun; 100(11):2292-9. PubMed ID: 15160331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
    Schilder CM; Schagen SB
    Minerva Ginecol; 2007 Aug; 59(4):387-401. PubMed ID: 17923830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.
    Schilder CM; Seynaeve C; Linn SC; Boogerd W; Beex LV; Gundy CM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
    Psychooncology; 2012 May; 21(5):479-87. PubMed ID: 21351188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
    Buwalda B; Schagen SB
    Life Sci; 2013 Oct; 93(17):581-8. PubMed ID: 23353876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer.
    Stewart A; Bielajew C; Collins B; Parkinson M; Tomiak E
    Clin Neuropsychol; 2006 Feb; 20(1):76-89. PubMed ID: 16410227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
    Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
    Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer.
    Noal S; Levy C; Hardouin A; Rieux C; Heutte N; Ségura C; Collet F; Allouache D; Switsers O; Delcambre C; Delozier T; Henry-Amar M; Joly F
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):795-803. PubMed ID: 20888704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment.
    Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
    Psychooncology; 2009 Feb; 18(2):134-43. PubMed ID: 18551510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive Deficits in Breast Cancer Survivors After Chemotherapy and Hormonal Therapy.
    Frank JS; Vance DE; Triebel KL; Meneses KM
    J Neurosci Nurs; 2015 Dec; 47(6):302-12. PubMed ID: 26447567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of cognitive decline after chemotherapy in breast cancer patients.
    Vearncombe KJ; Rolfe M; Wright M; Pachana NA; Andrew B; Beadle G
    J Int Neuropsychol Soc; 2009 Nov; 15(6):951-62. PubMed ID: 19709455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of adjuvant chemotherapy on cognition in women with breast cancer--preliminary results of an observational longitudinal study.
    Shilling V; Jenkins V; Morris R; Deutsch G; Bloomfield D
    Breast; 2005 Apr; 14(2):142-50. PubMed ID: 15767184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer.
    Kreukels BP; van Dam FS; Ridderinkhof KR; Boogerd W; Schagen SB
    Clin Breast Cancer; 2008 Feb; 8(1):80-7. PubMed ID: 18501062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study.
    Hermelink K; Henschel V; Untch M; Bauerfeind I; Lux MP; Munzel K
    Cancer; 2008 Nov; 113(9):2431-9. PubMed ID: 18823033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results.
    Weis J; Poppelreuter M; Bartsch HH
    Psychooncology; 2009 Jul; 18(7):775-82. PubMed ID: 19061196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.